Adriana H. Van Grunsven-Van Engen

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer.

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer.

Journal: Molecular oncology
Published: February 04, 2026

Real-world effectiveness of molecular-matched therapies in salivary gland cancer.

Real-world effectiveness of molecular-matched therapies in salivary gland cancer.

Journal: ESMO open
Published: January 08, 2026

SPIO-enhanced MRI for sentinel lymph node mapping in oral cancer: a prospective feasibility study.

SPIO-enhanced MRI for sentinel lymph node mapping in oral cancer: a prospective feasibility study.

Journal: European radiology experimental
Published: June 06, 2025

The effect of androgen blockade on [68Ga]Ga-PSMA-11 and [18F]FDG PET uptake in patients with recurrent or metastatic salivary duct carcinoma: a prospective imaging study.

The effect of androgen blockade on [68Ga]Ga-PSMA-11 and [18F]FDG PET uptake in patients with recurrent or metastatic salivary duct carcinoma: a prospective imaging study.

Journal: EJNMMI research
Published: February 25, 2025

A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.

A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.

Journal: BMC cancer
Published: July 25, 2024

Lutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study.

Lutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study.

Journal: Theranostics
Published: May 29, 2024

Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma.

Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma.

Journal: European thyroid journal
Published: May 13, 2024

Molecular Diagnostics and [18F]FDG-PET/CT in Indeterminate Thyroid Nodules: Complementing Techniques or Waste of Valuable Resources?

Molecular Diagnostics and [18F]FDG-PET/CT in Indeterminate Thyroid Nodules: Complementing Techniques or Waste of Valuable Resources?

Journal: Thyroid : official journal of the American Thyroid Association
Published: November 27, 2023

Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial.

Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial.

Journal: Oral oncology
Published: October 30, 2023

European experience with the Afirma Gene Expression Classifier for indeterminate thyroid nodules: A clinical utility study in the Netherlands.

European experience with the Afirma Gene Expression Classifier for indeterminate thyroid nodules: A clinical utility study in the Netherlands.

Journal: Head & neck
Published: December 19, 2022

Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors.

Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors.

Journal: Oral oncology
Published: September 14, 2022

Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients.

Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients.

Journal: Cancers
Published: July 12, 2022
Showing 1-12 of 46

Last Updated: 09/26/2026